Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

naprx Press Releases

  + XML/RSS  



By NAPSRx
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.

By NAPSRx
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.

By NAPSRx
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.

By NAPSRx
Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S.  based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement.

By NAPSRx
Acorda Therapeutics announced on September 24, 2014, their plans to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash.

By NAPSRx
Eli Lilly is a global healthcare leader committed to creating high-quality medicines that meet real needs.

By NAPSRx
Baxter and Halozyme have received approval of their subcutaneous treatment, HYQVIA to treat adult patients with primary immunodeficiency (PI).

By NAPSRx
Takeda Pharmaceuticals and Orexigen® Therapeutics, Inc  have announced the FDA  approval of Contrave®  ®(naltrexone HCI and bupropion HCI) extended release tablets to treat obese or overweight adults  with at least one...

By NAPSRx
Novartis heralds breakthrough clinical results with experimental drug to treat heart failure. ‘It’s been at least a decade since we've had a breakthrough of this magnitude,’’ said Dr. Clyde Yancy, cardiology chief at Northwestern University

By NAPSRx
Mylan is an industry leader in the generics and specialty pharmaceuticals market with sales in approximately 140 countries and territories.

By NAPSRx
According to Thomson Reuters, the pharmaceutical industry’s sales will amount to $1 Trillion in 2014.

By NAPSRx
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) has received FDA approval for Ferric Citrate (formerly known as Zerenex) to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

By NAPSRx
Keytruda, developed by Merck is intended for patients with advanced melanoma and who are unresponsive to other therapies.

By NAPSRx
The new life science division of Google called Calico will join forces with Abbvie to collaborate on the discovery, development and commercialization of new therapies in a research deal worth approximately $1.5 billion.

By NAPSRx
ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein and is currently marketed in the United States by Pfizer Inc.

By NAPSRx
Amgen is dedicated to discovering, developing, manufacturing and delivering innovative human therapeutics for patients with debilitating illnesses.

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Promacta® developed by GlaxoSmithKline (GSK) to treat a rare bone marrow disorder.

By NAPSRx
Roche looks to expand their respiratory portfolio by acquiring InterMune Inc, a California based biotechnology company and their lead product pirfenidone for idiopathic pulmonary fibrosis (IPF).

By NAPSRx
ViiV Healthcare is a global specialist company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) specializing in the treatment and care for people living with HIV.

By NAPSRx
Eliquis, a jointly developed therapy from Pfizer and Bristol-Myers Squibb has been approved by the FDA to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy.

All Press Releases

By NAPSRx
Johnson & Johnson (NYSE: JNJ) will spend $200 million for further expansion on their Ebola vaccine program at Janssen Pharmaceuticals.

By NAPSRx
The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) made a unanimous decision to support the approval of Novartis’ investigational selective interleukin-17A (IL-17A) inhibitor, AIN457...

By NAPSRx
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.

By NAPSRx
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.

By NAPSRx
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.

By NAPSRx
Benralizumab, AstraZeneca’s novel investigational monoclonal antibody to treat patients with severe, uncontrolled asthma and elevated levels of eosinophils (inflammatory white blood cell)  has produced optimistic safety and efficacy clinical data...

By NAPSRx
Chimerix, Inc. (Nasdaq:CMRX), is a biopharmaceutical company focused on developing and commercializing novel, oral antivirals in areas of high unmet medical need.

By NAPSRx
Novartis and Bristol-Myers Squibb will join forces on a clinical collaboration which involves evaluating the safety, tolerability and preliminary efficacy of Zykadia(TM), INC280 and EGF816 in combination with Bristol-Myers Squibb's investigational...

By NAPSRx
Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S.  based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement.

By NAPSRx
Acorda Therapeutics announced on September 24, 2014, their plans to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash.

By NAPSRx
A pharmaceutical sales rep is one of the most coveted positions one can achieve in the sales industry.  Companies are looking for qualified pharmaceutical sales executives to manage their accounts across the United States.

By NAPSRx
Eli Lilly is a global healthcare leader committed to creating high-quality medicines that meet real needs.

By NAPSRx
AstraZeneca  and  Nektar Therapeutics have announced FDA approval of MOVANTIK™ (naloxegol) tablets C-II to treat opioid-induced constipation in adult patients with chronic, non-cancer pain.

By NAPSRx
Baxter and Halozyme have received approval of their subcutaneous treatment, HYQVIA to treat adult patients with primary immunodeficiency (PI).

By NAPSRx
Takeda Pharmaceuticals and Orexigen® Therapeutics, Inc  have announced the FDA  approval of Contrave®  ®(naltrexone HCI and bupropion HCI) extended release tablets to treat obese or overweight adults  with at least one...

By NAPSRx
Novartis heralds breakthrough clinical results with experimental drug to treat heart failure. ‘It’s been at least a decade since we've had a breakthrough of this magnitude,’’ said Dr. Clyde Yancy, cardiology chief at Northwestern University

By NAPSRx
Mylan is an industry leader in the generics and specialty pharmaceuticals market with sales in approximately 140 countries and territories.

By NAPSRx
According to Thomson Reuters, the pharmaceutical industry’s sales will amount to $1 Trillion in 2014.

By NAPSRx
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) has received FDA approval for Ferric Citrate (formerly known as Zerenex) to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

By NAPSRx
Keytruda, developed by Merck is intended for patients with advanced melanoma and who are unresponsive to other therapies.

By NAPSRx
The new life science division of Google called Calico will join forces with Abbvie to collaborate on the discovery, development and commercialization of new therapies in a research deal worth approximately $1.5 billion.

By NAPSRx
Biotech giant Abbvie's collaborative deal with Infinity Pharmaceuticals to develop and market duvelisib is worth approximately $800 million.

By NAPSRx
ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein and is currently marketed in the United States by Pfizer Inc.

By NAPSRx
Amgen is dedicated to discovering, developing, manufacturing and delivering innovative human therapeutics for patients with debilitating illnesses.

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Promacta® developed by GlaxoSmithKline (GSK) to treat a rare bone marrow disorder.

By NAPSRx
Roche looks to expand their respiratory portfolio by acquiring InterMune Inc, a California based biotechnology company and their lead product pirfenidone for idiopathic pulmonary fibrosis (IPF).

By NAPSRx
ViiV Healthcare is a global specialist company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) specializing in the treatment and care for people living with HIV.

By NAPSRx
Eliquis, a jointly developed therapy from Pfizer and Bristol-Myers Squibb has been approved by the FDA to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE following initial therapy.

By NAPSRx
GlaxoSmithKline (GSK)– a world leader in the healthcare industry specializes in researching and developing vaccines, medicines and consumer healthcare products to improve people’s health and well-being.

By NAPSRx
Cerdelga™ is the only first-line oral therapy approved to treat adults with Type 1 Gaucher Disease, a rare genetic disorder that affects specific cells and organs in the body.

By NAPSRx
The investigational antibiotic CAZ-AVI was studied in patients with intra-abdominal infections (cIAI).

By NAPSRx
Based on favorable results obtained from the ADVANCE Phase 3 Study, the FDA approval of PLEGRIDY™ signifies a blockbuster therapeutic achievement for Biogen Idec .

By NAPSRx
Merck specializes in developing new therapies that treat and prevent diseases to help people in need around the world.

By NAPSRx
Industry leader Sanofi and MannKind Corp have agreed to a enter into a global licensing agreement to develop and market AFREZZA® (Insulin human) rapid- acting inhaled insulin.

By NAPSRx
INVOKAMET™ developed by Johnson & Johnson has been approved by the FDA based on phase 3 studies which indicated the drug lowered blood sugar and is linked to significant reductions in body weight and systolic blood pressure.

By NAPSRx
The collaboration between Daiichi Sankyo and Charleston Labs marks a significant venture for the pain management market.

By NAPSRx
The Medicine Company has secured FDA approval for ORBACTIV adding to their product pipeline of innovative medicines worldwide.

By NAPSRx
Jardiance® (empagliflozin), a joint therapeutic venture from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly has been approved to reduce blood sugar levels in adult patients with type 2 diabetes.

By NAPSRx
AstraZeneca’s respiratory franchise is expected to see a significant boost with the assumption of Almirall’s pipeline of novel respiratory assets.

By NAPSRx
IMBRUVICA®, a jointly developed therapy from Pharmacyclics, Inc. and Janssen Biotech received full Approval based on Phase 3 RESONATE™ study data

By NAPSRx
Abbvie is a global biopharmaceutical specializing in the discovery and advancement of innovative therapies to meet the health needs of people and societies around the globe.

By NAPSRx
Gilead Sciences, Inc. is a biopharmaceutical company whose main focus is centered on discovering, developing and commercializing innovative therapeutics in areas of unmet medical need.

By NAPSRx
Biogen Idec specializes in the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.

By NAPSRx
Pharmaceutical Sales is one of the highest paid professions in sales and earnings are expected to increase in the coming years. Now is the time to get into this amazing field.

By NAPSR
Viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.

By NAPRx
New methods of testing have sped up the product cycle, as well as the need for more pharmaceutical representatives. Certified National Pharmaceutical Representatives are needed for the promotion of these new products coming through the pipelines.

By NAPRx
Certified National Pharmaceutical Representatives (CNPR) are needed for the booming bio pharmaceuticals sales industry. The National Association of Pharmaceutical Representatives (NAPRx) educates candidates trying to break into the industry.

By NAPRx
At an average earning of above 100,000 $ a year (w/ commission), Pharmaceutical Sales is one of the highest paid profession in sales. And earnings are said to increase in the coming years. Now is the time to get into this amazing field.

By NAPRx
The top pharmaceutical companies in the industry are looking for Certified National Pharmaceutical Representatives to promote their product lines. CNPR's possess the qualifications needed for success in the sales field.

By NAPRx
The Princeton Review announces the PRO's of being a pharmaceutical sales rep. Saying "excessive profit margins of many brand-name pharmaceutical products can mean enormous commissions", many are flocking to take and receive their CNPR Certification



Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share